INTRODUCTION: Little is known about the natural history of malignant solitary pulmonary nodules (SPN). Experts' beliefs may help fill these knowledge gaps and explain variation in clinical practices. METHODS: Using a modified Delphi process, we surveyed a group of lung cancer experts about tumor growth, disease progression, and prognosis in patients with malignant SPN. After completing the first survey, experts were given the opportunity during a second survey to revise their responses in light of their peers' beliefs. RESULTS: The response rate was 100% (14 of 14) for both surveys. There was consensus that disease progression depends on the tumor growth rate, that survival for patients with untreated lung cancer is approximated by a declining exponential function, and that treatment is delayed by approximately 1 tumor volume doubling time (TVDT) in patients who undergo a period of "watchful waiting." Just over half of experts (8 of 14) agreed that lung cancer progresses in three steps (from local to regional to distant disease), whereas 43% (6 of 14) preferred a 2-step model (from local to systemic disease). Likewise, 64% of experts (9 of 14) believed that malignant nodules grow exponentially, whereas 36% (5 of 14) believed that growth is slower than exponential. Experts' estimates of the risk of disease progression during a period of observation lasting 1 TVDT varied from 1 to 50%. Estimates of 5-year survival for patients in whom diagnosis and treatment were delayed by 1 TVDT varied between 40% and 80%. CONCLUSIONS: There is substantial variability in experts' beliefs about the natural history of untreated, malignant SPN. Different beliefs may be partly responsible for variation in management practices.
INTRODUCTION: Little is known about the natural history of malignant solitary pulmonary nodules (SPN). Experts' beliefs may help fill these knowledge gaps and explain variation in clinical practices. METHODS: Using a modified Delphi process, we surveyed a group of lung cancer experts about tumor growth, disease progression, and prognosis in patients with malignant SPN. After completing the first survey, experts were given the opportunity during a second survey to revise their responses in light of their peers' beliefs. RESULTS: The response rate was 100% (14 of 14) for both surveys. There was consensus that disease progression depends on the tumor growth rate, that survival for patients with untreated lung cancer is approximated by a declining exponential function, and that treatment is delayed by approximately 1 tumor volume doubling time (TVDT) in patients who undergo a period of "watchful waiting." Just over half of experts (8 of 14) agreed that lung cancer progresses in three steps (from local to regional to distant disease), whereas 43% (6 of 14) preferred a 2-step model (from local to systemic disease). Likewise, 64% of experts (9 of 14) believed that malignant nodules grow exponentially, whereas 36% (5 of 14) believed that growth is slower than exponential. Experts' estimates of the risk of disease progression during a period of observation lasting 1 TVDT varied from 1 to 50%. Estimates of 5-year survival for patients in whom diagnosis and treatment were delayed by 1 TVDT varied between 40% and 80%. CONCLUSIONS: There is substantial variability in experts' beliefs about the natural history of untreated, malignant SPN. Different beliefs may be partly responsible for variation in management practices.
Authors: M K Murphy; N A Black; D L Lamping; C M McKee; C F Sanderson; J Askham; T Marteau Journal: Health Technol Assess Date: 1998 Impact factor: 4.014
Authors: M H Baumann; C Strange; J E Heffner; R Light; T J Kirby; J Klein; J D Luketich; E A Panacek; S A Sahn Journal: Chest Date: 2001-02 Impact factor: 9.410
Authors: Michael K Gould; James Fletcher; Mark D Iannettoni; William R Lynch; David E Midthun; David P Naidich; David E Ost Journal: Chest Date: 2007-09 Impact factor: 9.410
Authors: Michael K Gould; Gillian D Sanders; Paul G Barnett; Chara E Rydzak; Courtney C Maclean; Mark B McClellan; Douglas K Owens Journal: Ann Intern Med Date: 2003-05-06 Impact factor: 25.391
Authors: Anthony Cousien; Dorothée Obach; Sylvie Deuffic-Burban; Aya Mostafa; Gamal Esmat; Valérie Canva; Mohamed El Kassas; Mohammad El-Sayed; Wagida A Anwar; Arnaud Fontanet; Mostafa K Mohamed; Yazdan Yazdanpanah Journal: BMC Med Res Methodol Date: 2014-03-17 Impact factor: 4.615
Authors: Gerard A Silvestri; Nichole T Tanner; Paul Kearney; Anil Vachani; Pierre P Massion; Alexander Porter; Steven C Springmeyer; Kenneth C Fang; David Midthun; Peter J Mazzone Journal: Chest Date: 2018-03-01 Impact factor: 9.410